Dongxing Zha
About Dongxing Zha
Dongxing Zha is the CTO of TCR Discovery and Engineering, CEO of Keyway TCR Discovery, and founder of Ypsilon Therapeutics, with expertise in TCR-based therapeutics and antibody discovery.
Title: Dongxing Zha, CTO of TCR Discovery and Engineering and CEO of Keyway TCR Discovery
Dongxing Zha holds the position of Chief Technology Officer (CTO) at TCR Discovery and Engineering. Additionally, he serves as the Chief Executive Officer (CEO) at Keyway TCR Discovery. In these roles, he oversees the strategic direction and technological advancements of the respective companies.
Dongxing Zha's Education and Expertise
Dongxing Zha earned a PhD, signaling his advanced knowledge and research capabilities. He is an expert in the field of T-cell receptor (TCR)-based therapeutics and has contributed to the development of TCR mimic (TCRm) discovery services. His expertise extends to antibody discovery, bispecific cell engagers, and CAR-T engineering.
Dongxing Zha's Role in TCR-Based Therapeutics
Dongxing Zha is deeply involved in the discovery and engineering of TCR-based therapeutics. He works on engineering and functional testing for TCRm therapeutics, focusing on translating research into practical medical applications. His work includes creating multiple proprietary T-cell engagers and developing mRNA- and lentiviral-based vector systems for CAR-T therapies.
Founder of Ypsilon Therapeutics: Dongxing Zha
Dongxing Zha is the founder of Ypsilon Therapeutics, reflecting his entrepreneurial spirit and commitment to advancing therapeutic technologies. Under his leadership, Ypsilon Therapeutics focuses on groundbreaking research and development in the field of TCR-based therapies.
Dongxing Zha's Contributions to Translational Medicine
In his career, Dongxing Zha has made significant contributions to translational medicine, particularly in the in vivo and in vitro functional testing of therapeutic candidates. His efforts facilitate the bridge between laboratory research and clinical application, aiming to turn scientific discoveries into actionable treatments.